Cangrelor

Cangrelor is a medication used to prevent blood clots in patients undergoing certain types of surgery or procedures. It belongs to a class of drugs known as antiplatelet agents, specifically a selective platelet P2Y12 receptor antagonist. Cangrelor works by inhibiting the aggregation of platelets, which are blood cells that play a crucial role in blood clotting. By preventing platelets from clumping together, cangrelor helps to reduce the risk of clot formation, which is particularly important in patients who are at high risk of developing clots, such as those with coronary artery disease or those undergoing high-risk surgical procedures.

Cangrelor is administered intravenously and is typically used in conjunction with other antiplatelet medications or anticoagulants. It is available in a ready-to-use solution that is administered through an intravenous infusion. The medication has a relatively short half-life, which means it is quickly metabolized and eliminated from the body, allowing for rapid reversal of its effects if necessary.

The most common side effects of cangrelor include headache, dizziness, and nausea. Serious side effects are rare but can include allergic reactions, low blood pressure, and bleeding. As with any medication, it is important for patients to discuss the potential benefits and risks of cangrelor with their healthcare provider before use.

Cangrelor was approved by the U.S. Food and Drug Administration (FDA) in 2007 and is marketed under the brand name Xigduo. It is manufactured by Eli Lilly and Company. The medication is available by prescription only and should be used under the supervision of a healthcare professional.